In Depth Research on Global Cancer Vaccine Market & Clinical Trial Insight

“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:

* Global Cancer Market Overview
* Emergence of Personalized Cancer Vaccines
* Platforms for Cancer Vaccines Delivery
* Mechanism of Cancer Vaccines
* Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
* Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
* Marketed Cancer Vaccines: 15 Vaccines
* Regulatory Framework for Cancer Vaccines Development & Marketing

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report----Global-Cancer-Vaccine-Market-&-Clinical-Trial-Insight.php

Table of Contents

1. Introduction to Cancer Vaacines

2. Mechanism of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Adjuvants Therapy for Cancer Vaccines

4. Global Cancer Vaccines Market Overview
4.1 Current Market Scenario
4.2 Global Cancer Vaccine Drug Pipeline by Indication

5. Emergence of Personalized Cancer Vaccines

6. Public HPV Cancer Vaccination Program

7. Global Cancer Vaccines Market Dynamics
7.1 Favorable Market Parameters
7.1.1 Pottential Demand for Cancer Vaccines
7.1.2 Public Cancer Vaccination Program
7.1.3 Advancements in Development Technology
7.1.4 Personalized Cancer Vaccines
7.1.5 Myriad of Demographs for Cancer Vaccine Development
7.2 Commercialization Challenges

8. Global Cancer Vaccine Market Future Outlook

9. Bladder Cancer Vaccine Clinical Pipeline Insight by Company & Phase
9.1 Phase-II

10. Blood Cancer Vaccine Clinical Pipeline Insight by Company & Phase
10.1 Research till Preregistration

11. Brain Cancer Vaccine Clinical Pipeline Insight by Company & Phase
11.1 Preclinical Till Phase-III

12. Breast Cancer Vaccine Clinical Pipeline Insight by Company & Phase
12.1 Preclinical till Phase-III

13. Cancer Vaccine Clinical Pipeline Insight by Company & Phase
13.1 Research till Phase-II

14. Cervical Cancer Vaccine Clinical Pipeline Insight by Company & Phase
14.1 Phase-II

15. Colorectal Cancer Vaccine Clinical Pipeline Insight by Company & Phase
15.1 Preclinical till Preregistration

16. Head and Neck Cancer Vaccine Clinical Pipeline Insight by Company & Phase
16.1 Preclinical till Phase-I/II

17. Liver Cancer Vaccine Clinical Pipeline Insight by Company & Phase
17.1 Phase-I till Phase-II

18. Lung Cancer Vaccine Clinical Pipeline Insight by Company & Phase
18.1 Preclinical till Phase-III

19. Oesophageal Cancer Vaccine Clinical Pipeline Insight by Company & Phase
19.1 Phase-III

20. Ovarian Cancer Vaccine Clinical Pipeline Insight by Company & Phase
20.1 Preclinical till Phase-III

21. Pancreatic Cancer Vaccine Clinical Pipeline Insight by Company & Phase
21.1 Reseach till Phase-III

22. Prostate Cancer Vaccine Clinical Pipeline Insight by Company & Phase
22.1 Preclinical till Phase-III

23. Renal Cancer Vaccine Clinical Pipeline Insight by Company & Phase
23.1 Phase-I till Phase-III

24. Sarcoma Vaccine Clinical Pipeline Insight by Company & Phase
24.1 Phase-II

25. Skin Cancer Vaccine Clinical Pipeline Insight by Company & Phase
25.1 Preclinical till Phase-III

26. Solid Tumours Vaccine Clinical Pipeline Insight by Company & Phase
26.1 Preclinical till Phase-II

27. Multiple Cancer Vaccine Clinical Pipeline Insight by Company & Phase
27.1 Preclinical till Phase-III

28. Marketed Cancer Vaccine Clinical Insight by Company & Indication
28.1 Bladder Cancer
28.1.1 BCG Bladder Cancer Vaccine (Immucyst® & TheraCys®)
28.1.2 Bladder Cancer Vaccine (PACIS®)
28.1.3 Bladder Cancer Vaccine - Organon Teknika

28.2 Cervical Cancer
28.2.1 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)

28.3 Lung Cancer
28.3.1 BV NSCLC 001
28.3.2 Cadi 05 (Immuvac® & Mycidac-C™)
28.3.3 Racotumomab (Vaxira®)

28.4 Pancreatic Cancer
28.4.1 Tertomotide (LucaVax)

28.5 Prostate Cancer
28.5.1 Sipuleucel-T (Provenge®)

28.6 Renal Cancer
28.6.1 Renal Cancer Vaccine (Reniale®)
28.6.2 Vitespen (Oncophage®)

28.7 Skin Cancer
28.7.1 Melanoma Vaccine (MVax®)
28.7.2 Melanoma Vaccine (Melacine®)

28.8 Multiple Cancer
28.8.1 Human Papillomavirus Vaccine 9-Valent (V503) (GARDASIL®9)
28.8.2 Human Papillomavirus Vaccine Quadrivalent (Gardasil® & Silgard®)

29. Discontinued & Suspended Cancer Vaccine Drug Clinical Pipeline Insight
29.1 No Development Reported
29.2 Discontinued
29.3 Suspended

30. FDA Regulatory Framework for Cancer Vaccines Development & Marketing
30.1 Considerations for both Early and Late Phase Clinical Trials
30.1.1 Patient Population
30.1.2 Monitoring the Immune Response
30.1.3 Biomarkers as Evidence Of Efficacy
30.1.4 Adjuvants Used To Stimulate Immune Response
30.1.5 Multi-Antigen Vaccines
30.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
30.1.7 Concomitant and Subsequent Therapies

30.2 Considerations for Early Phase Clinical Trials
30.2.1 Starting Dose and Dosing Schedule
30.2.2 Booster and Maintenance Therapy
30.2.3 Dose Escalation
30.2.4 Single-Arm versus Randomized Phase 2 Trials In Early Development

30.3 Considerations for Late Phase Clinical Trials
30.3.1 Safety Profile from Early Phase Clinical Trials
30.3.2 Endpoints
30.3.3 Statistical Issues
30.3.4 Control Issues
30.3.5 Delayed Vaccine Effect
30.3.6 Autologous Vaccine Trials
30.3.7 Accelerated Approval Regulations

31. Competitive Landscape: Business Overview & Product Pipeline
31.1 Advaxis
31.2 AVAX Technologies
31.3 Celldex Therapeutics
31.4 Dendreon Corporation
31.5 Galena Biopharma
31.6 GlaxoSmithKline
31.7 ImmunoCellular Therapeutics
31.8 ImmunoGen
31.9 Inovio Pharmaceuticals
31.10 KAEL-GemVax
31.11 Liponova
31.12 MedImmune
31.13 Merck
31.14 NeoStem Oncology
31.15 NewLink Genetics
31.16 Northwest Biotherapeutics
31.17 Novartis
31.18 Peregrine Pharmaceuticals
31.19 Recombio
31.20 Roche
31.21 Sanofi
31.22 Seattle Genetics
31.23 Valeant Pharmaceuticals

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 4-1: Global Cancer Vaccines Market (US$ Billion), 2014-2020
Figure 4-2: Global Cancer Vaccines Market by Region (%), 2014 & 2020
Figure 4-3: Examples of Commercially Available Cancer Vaccines
Figure 4-4: Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-5: Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-6: Bladder Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-7: Bladder Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-8: Blood Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-9: Blood Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-10: Brain Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-11: Brain Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-12: Breast Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-13: Breast Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-14: Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-15: Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-16: Cervical Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-17: Cervical Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-18: Colorecta Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-19: Colorecta Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-20: Head & Neck Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-21: Head & Neck Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-22: Liver Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-23: Liver Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-24: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-25: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-26: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-27: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-28: Pancreatic Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-29: Pancreatic Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-30: Prostate Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-31: Prostate Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-32: Renal Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-33: Renal Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-34: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-35: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-36: Solid Tumour Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-37: Solid Tumour Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-38: Multiple Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-39: Multiple Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-40: No Development Reported Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-41: No Development Reported Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-42: Discontinued Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-43: Discontinued Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 4-44: Suspended Cancer Vaccine Drug Pipeline by Phase (%), 2015
Figure 4-45: Suspended Cancer Vaccine Drug Pipeline by Phase (Number), 2015
Figure 5-1: Overview of Personalized Cancer Vaccines Development
Figure 5-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 5-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Figure 6-1: Prophylactic Cancer Vaccines Available for Different Serotypes of HPV
Figure 7-1: Factors Responsible for High Demand of Cancer Vaccines
Figure 31-1: Advaxis Clinical Pipeline
Figure 31-2: Celldex Therapeutics Clinical Pipeline
Figure 31-3: Galena Biopharma Clinical Pipeline
Figure 31-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 31-5: ImmunoGen Clinical Pipeline
Figure 31-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 31-7: KAEL-Gemvax Clinical Pipeline
Figure 31-8: NewLink Genetics Corporation Clinical Pipeline
Figure 31-9: Northwest Biotherapeutics Clinical Pipeline
Figure 31-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 31-11: Seattle Genetics Clinical Pipeline

Table 5-1: Different Types of Biomarkers For Personalized Cancer Vaccine Development

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India

This release was published on openPR.